GlassScriptPhysician profile
Anthony M Santilli
NPI 1356360663
$1,738.68
in general payments reported to CMS, 2019-2025
16 companies · $617 in 2025
The $617 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $143 · 2021: $164 · 2022: $177 · 2023: $305 · 2024: $196 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,117.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $521.52 | 2019-2025 | Nucala, Trelegy Ellipta |
| Abbvie INC. | $304.82 | 2023-2025 | Teflaro, Avycaz |
| Novartis Pharmaceuticals Corporation | $223.24 | 2019-2025 | |
| Pulmonx Corporation | $142.56 | 2023 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Galvanize Therapeutics, INC | $106.62 | 2025 | Aliya System |
| Janssen Pharmaceuticals, INC | $76.60 | 2019-2024 | Xarelto |
| Amgen INC. | $67.44 | 2025 | Tezspire |
| Genzyme Corporation | $63.42 | 2019-2022 | |
| Genentech USA, INC. | $54.77 | 2019-2023 | Xolair |
| Astrazeneca Pharmaceuticals LP | $37.50 | 2020-2025 | Airsupra |
| Electromed, INC. | $37.33 | 2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $31.32 | 2022-2025 | Opsumit, Uptravi |
| Insmed, INC. | $29.06 | 2022-2023 | Arikayce |
| Lilly USA, LLC | $21.30 | 2025 | Zepbound |
| Teva Pharmaceuticals USA, INC. | $21.18 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$100,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Santilli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.